Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab phase 3 study in recent-onset type 1 diabetes
NL-OMON35199Phase 3Withdrawn
- Sponsor
- MacroGenics
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of teplizumab in diabetes mellitus type 1 (T1D) (4 arms), sponsored by MacroGenics. Primary endpoints: Composite insulin dose and HbA1c responder rate at 52 weeks and Mean HbA1c at 52 weeks. Planned start Nov 2009; status: withdrawn.
02
Drugs
teplizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON35199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35199.